Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Karuna Therapeutics Inc is a biotechnology business based in the US. Karuna Therapeutics shares (KRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Karuna Therapeutics employs 63 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$132.18|
|52-week range||$77.85 - $146.97|
|50-day moving average||$120.74|
|200-day moving average||$116.85|
|Wall St. target price||$158.60|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.89|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||2.91%|
|1 month (2021-09-27)||7.63%|
|3 months (2021-07-27)||19.00%|
|6 months (2021-04-27)||17.52%|
|1 year (2020-10-26)||65.29%|
|2 years (2019-10-25)||808.45%|
|3 years (2018-10-23)||N/A|
|5 years (2016-10-23)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-13.93%|
|Return on equity TTM||-23.12%|
|Market capitalisation||$3.9 billion|
TTM: trailing 12 months
There are currently 1.7 million Karuna Therapeutics shares held short by investors – that's known as Karuna Therapeutics's "short interest". This figure is 0.1% down from 1.7 million last month.
There are a few different ways that this level of interest in shorting Karuna Therapeutics shares can be evaluated.
Karuna Therapeutics's "short interest ratio" (SIR) is the quantity of Karuna Therapeutics shares currently shorted divided by the average quantity of Karuna Therapeutics shares traded daily (recently around 116966.90042076). Karuna Therapeutics's SIR currently stands at 14.26. In other words for every 100,000 Karuna Therapeutics shares traded daily on the market, roughly 14260 shares are currently held short.
However Karuna Therapeutics's short interest can also be evaluated against the total number of Karuna Therapeutics shares, or, against the total number of tradable Karuna Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Karuna Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Karuna Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0733% of the tradable shares (for every 100,000 tradable Karuna Therapeutics shares, roughly 73 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Karuna Therapeutics.
Find out more about how you can short Karuna Therapeutics stock.
We're not expecting Karuna Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Karuna Therapeutics's shares have ranged in value from as little as $77.85 up to $146.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Karuna Therapeutics's is 1.7953. This would suggest that Karuna Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Karuna Therapeutics, Inc. , a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.